| Bioactivity | JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283[1]. |
| Target | JAK. |
| In Vivo | JAK-IN-5 hydrochloride (compound 1) (oral aspirate, 0.5 mg/mL, 50 μL ) inhibits STAT6 phosphorylation by 60% in IL-13-induced in lung tissue in a mouse model of pSTAT6 induction[2].JAK-IN-5 hydrochloride (compound 1) (oral aspirate, 0.1-1.0 mg/mL, 50 μL) inhibits 88% of BALF eosinophils in male C57 mice model of Alternaria alternata-induced eosinophilic inflammation of the lung[2]. |
| Name | JAK-IN-5 hydrochloride |
| Formula | C27H32ClFN6O |
| Molar Mass | 511.03 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Paul R. Fatheree, et al. JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease. US20170121327A1. [2]. Venkat R, et al. Methods of treatment using a jak inhibitor compound. US20180311226. |